Carcinoma, Non-Small-Cell Lung

• 

  Subject Areas on Research

  • 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 
  • 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. 
  • 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. 
  • A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. 
  • A Minimally Invasive Approach to Lobectomy After Induction Therapy Does Not Compromise Survival. 
  • A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer. 
  • A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. 
  • A National Analysis of Minimally Invasive Vs Open Segmentectomy for Stage IA Non-Small-Cell Lung Cancer. 
  • A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Clinical Stage II Non-Small-Cell Lung Cancer. 
  • A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. 
  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. 
  • A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. 
  • A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer. 
  • A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. 
  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 
  • A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. 
  • A functional variant of tandem repeats in human telomerase gene was associated with survival of patients with early stages of non-small cell lung cancer. 
  • A genetic algorithm for variable selection in logistic regression analysis of radiotherapy treatment outcomes. 
  • A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. 
  • A hypothesis: indirect cell death in the radiosurgery era. 
  • A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. 
  • A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. 
  • A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. 
  • A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. 
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. 
  • A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 
  • A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer. 
  • A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). 
  • A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. 
  • A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. 
  • A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. 
  • A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. 
  • A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. 
  • A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. 
  • A prospective comparison of fiberoptic transbronchial needle aspiration and bronchial biopsy for bronchoscopically visible lung carcinoma. 
  • A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. 
  • A review of glioblastoma immunotherapy. 
  • A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates. 
  • A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. 
  • A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. 
  • A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. 
  • A stitch (or scan) in time saves nine. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival. 
  • ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Aberrant promoter methylation of multiple genes in non-small cell lung cancers. 
  • Absence of correlation between nuclear morphometry and survival in stage I non-small cell lung carcinoma. 
  • Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy. 
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 
  • Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study. 
  • Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. 
  • Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. 
  • Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. 
  • Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant therapies for non-small cell lung cancer: introduction. 
  • Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation. 
  • Advances in radiotherapy for tumors involving the mediastinum. 
  • Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. 
  • Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. 
  • Age differences in care practices and outcomes for hospitalized patients with cancer. 
  • Age- and sex-specific genomic profiles in non-small cell lung cancer. 
  • Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. 
  • All evidence points to the need for collaborative care. 
  • Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. 
  • Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. 
  • Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. 
  • Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. 
  • Alternatives to Lobectomy for High-Risk Patients With Early-Stage Non-Small Cell Lung Cancer. 
  • An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. 
  • An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. 
  • An Exploratory Radiomics Approach to Quantifying Pulmonary Function in CT Images. 
  • An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. 
  • Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. 
  • Anemia and lung cancer. 
  • Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. 
  • Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. 
  • Angiogenesis in non-small cell lung cancer. 
  • Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? 
  • Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. 
  • Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. 
  • Association between polymorphisms in the GSTA4 gene and risk of lung cancer: a case-control study in a Southeastern Chinese population. 
  • Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. 
  • Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. 
  • Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. 
  • Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. 
  • Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: Analysis of the National Cancer Database. 
  • Association of pre-treatment radiomic features with lung cancer recurrence following stereotactic body radiation therapy. 
  • Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. 
  • Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. 
  • Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway. 
  • Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. 
  • Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. 
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. 
  • Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. 
  • Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. 
  • Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? 
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. 
  • CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. 
  • CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. 
  • CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. 
  • Cancer cachexia: Are we ready to take a step forward? 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Carbonic anhydrase IX in early-stage non-small cell lung cancer. 
  • Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. 
  • Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. 
  • Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 
  • Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 
  • Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. 
  • Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. 
  • Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Challenging 30-day mortality as a site-specific quality metric in non-small cell lung cancer. 
  • Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study. 
  • Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. 
  • Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. 
  • Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. 
  • Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. 
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 
  • Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. 
  • Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. 
  • Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. 
  • Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. 
  • Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. 
  • Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. 
  • Clinical and dosimetric predictors of radiation-induced esophageal toxicity. 
  • Clinical applications of PET in oncology. 
  • Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration. 
  • Clinical practice. Lung cancer screening. 
  • Clinical prognostic model for older patients with advanced non-small cell lung cancer. 
  • Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. 
  • Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 
  • Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). 
  • Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). 
  • Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. 
  • Combining immunotherapy and radiotherapy for the STAR treatment. 
  • Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors. 
  • Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance? 
  • Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance. 
  • Commentary: Surgery for small cell lung cancer: This is the way. 
  • Commentary: Survival after small cell lung cancer resection: Small opportunity? 
  • Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis. 
  • Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. 
  • Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. 
  • Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. 
  • Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Complement factor H autoantibodies are associated with early stage NSCLC. 
  • Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. 
  • Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. 
  • Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. 
  • Conflict of interest disclosures. 
  • Consensus on medical treatment of non-small cell lung cancer. 
  • Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. 
  • Contouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study. 
  • Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. 
  • Controversial issues regarding the use of induction chemotherapy for lung cancer. 
  • Correction for Systematic Bias in Radiomics Measurements Due to Variation in Imaging Protocols. 
  • Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer. 
  • Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. 
  • Correlation of Regional Lung Ventilation and Gas Transfer to Red Blood Cells: Implications for Functional-Avoidance Radiation Therapy Planning. 
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. 
  • Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. 
  • Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. 
  • Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. 
  • Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS. 
  • DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. 
  • De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. 
  • Defining and improving postoperative care. 
  • Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial. 
  • Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. 
  • Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness. 
  • Depression after successful treatment for nonsmall cell lung carcinoma. 
  • Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. 
  • Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. 
  • Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. 
  • Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). 
  • Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. 
  • Detection of occult N2 disease with molecular techniques. 
  • Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. 
  • Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. 
  • Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. 
  • Dishevelled-3 activates p65 to upregulate p120-catenin transcription via a p38-dependent pathway in non-small cell lung cancer. 
  • Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery. 
  • Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. 
  • Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 
  • Diurnal cortisol rhythm as a predictor of lung cancer survival. 
  • Divergent Interpretations of Imaging After Stereotactic Body Radiation Therapy for Lung Cancer. 
  • Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. 
  • Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). 
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. 
  • Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival? 
  • Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? 
  • Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors. 
  • Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. 
  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. 
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. 
  • EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. 
  • Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. 
  • Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. 
  • Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. 
  • Educational outcomes in the era of the Affordable Care Act: impact of personalized education about non-small cell lung cancer. 
  • Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis. 
  • Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. 
  • Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. 
  • Effect of tube current on computed tomography radiomic features. 
  • Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study. 
  • Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 
  • Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. 
  • Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason. 
  • Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. 
  • Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. 
  • Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. 
  • Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. 
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. 
  • Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 
  • Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 
  • Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer. 
  • Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. 
  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). 
  • Estimating overdiagnosis in lung cancer screening--reply. 
  • Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. 
  • Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: calculations from clinical trials. 
  • Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. 
  • Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. 
  • Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. 
  • Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). 
  • Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. 
  • Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. 
  • Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. 
  • Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. 
  • Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. 
  • Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. 
  • Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer. Reply. 
  • FDG PET of pleural effusions in patients with non-small cell lung cancer. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. 
  • Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. 
  • Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. 
  • Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. 
  • Feasibility of hybrid thoracoscopic lobectomy and en-bloc chest wall resection. 
  • Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. 
  • Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. 
  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. 
  • First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. 
  • First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. 
  • First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. 
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. 
  • Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. 
  • Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. 
  • Frequency and prognostic significance of preoperatively detected enlarged regional lymph nodes in patients with pathological stage I non-small cell lung cancer following resection. 
  • Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies. 
  • Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. 
  • Functional imaging in lung cancer. 
  • Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. 
  • Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. 
  • Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gefitinib therapy for non-small cell lung cancer. 
  • Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC. 
  • Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. 
  • Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. 
  • Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients. 
  • Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. 
  • Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small cell lung carcinoma. 
  • Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival. 
  • Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer. 
  • Genetic variants of JNK and p38α pathways and risk of non-small cell lung cancer in an Eastern Chinese population. 
  • Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study. 
  • Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. 
  • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. 
  • Genomic signatures in non-small-cell lung cancer: targeting the targeted therapies. 
  • Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. 
  • Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. 
  • HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. 
  • HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. 
  • Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. 
  • Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. 
  • Heart rate decrease during crizotinib treatment and potential correlation to clinical response. 
  • Helping patients take control of their medical records. A case study of a personal health organizer. 
  • High frequency of bronchogenic carcinoma after single-lung transplantation. 
  • High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. 
  • High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. 
  • Higher Use of Surgery Confers Superior Survival in Stage I Non-Small Cell Lung Cancer. 
  • Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 
  • Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • How Good Is Positron Emission Tomography at Detecting Previously-Occult Metastatic Lung Cancer at Diagnosis? 
  • How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. 
  • Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. 
  • Hyperpolarized 129 Xe gas transfer MRI: the transition from 1.5T to 3T. 
  • Hyperpolarized 129Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans. 
  • Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. 
  • Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. 
  • Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. 
  • Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. 
  • If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. 
  • If histology matters.. 
  • Images in clinical medicine. Malignant pericardial effusion. 
  • Imaging bronchogenic carcinoma. 
  • Imaging lung cancer. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 
  • Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. 
  • Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. 
  • Immunotoxin Therapy for Lung Cancer. 
  • Impact of Chest Wall Resection on Mortality After Lung Resection for Non-Small Cell Lung Cancer. 
  • Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. 
  • Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. 
  • Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. 
  • Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival. 
  • Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. 
  • Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. 
  • In Reply to Giron et al. 
  • In reply to Kumar et al. 
  • In reply to Robins et al. 
  • In situ detection of Epstein-Barr virus in non-small cell lung carcinomas. 
  • Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. 
  • Incorporation of functional imaging data in the evaluation of dose distributions using the generalized concept of equivalent uniform dose. 
  • Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer. 
  • Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. 
  • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. 
  • Induction chemotherapy for T3N0M0 non-small-cell lung cancer increases the rate of complete resection but does not confer improved survival. 
  • Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. 
  • Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. 
  • Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. 
  • Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Initial and Longitudinal Cost of Surgical Resection for Lung Cancer. 
  • Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). 
  • Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. 
  • Intercellular junctions and tumor behavior in lung cancer. 
  • Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. 
  • Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. 
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Invasive Mediastinal Staging for Lung Cancer by The Society of Thoracic Surgeons Database Participants. 
  • Invasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. 
  • Invited Commentary. 
  • Invited Commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? 
  • Just buckle up. 
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. 
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 
  • Less is more: a shift in the surgical approach to non-small-cell lung cancer. 
  • Less is sometimes less. 
  • Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. 
  • Lobectomy by Video-Assisted Thoracic Surgery or Muscle-Sparing Thoracotomy for Stage 1 Lung Cancer: Could Cost-Effectiveness Give the Answer? 
  • Local control without resection. 
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy. 
  • Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
  • Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. 
  • Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. 
  • Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. 
  • Location of the Tumor is a "Central" Predictor of Nodal (N1) Upstaging. 
  • Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. 
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. 
  • Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. 
  • Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. 
  • Lung cancer in North Carolina. 
  • Lung cancer management in 2010. 
  • Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. 
  • Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. 
  • MET and phosphorylated MET as potential biomarkers in lung cancer. 
  • Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Management of unresectable non-small cell carcinoma of the lung (NSCLC). 
  • Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. 
  • Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. 
  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. 
  • Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. 
  • Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. 
  • Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors. 
  • Metastasis of Lung Adenocarcinoma to the Lacrimal Sac. 
  • Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. 
  • Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Mind-mapping for lung cancer: towards a personalized therapeutics approach. 
  • Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. 
  • Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database. 
  • Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. 
  • Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation? 
  • Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. 
  • Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. 
  • Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. 
  • Molecular biologic staging of lung cancer. 
  • Molecular biologic substaging of non-small cell lung cancer. 
  • Molecular biologic substaging of stage I NSCLC through immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue. 
  • Molecular biologic substaging of stage I lung cancer according to gender and histology. 
  • Molecular characterization of the human delta opioid receptor in lung cancer. 
  • Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. 
  • Molecular staging and the selection of therapy for non-small cell lung cancer. 
  • Molecular staging of lung and esophageal cancer. 
  • Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. 
  • Morphometric quantitation of tumor necrosis in stage 1 non-small cell carcinoma of lung: prognostic implications. 
  • Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. 
  • Mutational hotspots in the mitochondrial genome of lung cancer. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 
  • Neighborhood-level socioeconomic determinants impact outcomes in nonsmall cell lung cancer patients in the Southeastern United States. 
  • Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. 
  • Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. 
  • Next-generation Tumor-homing Induced Neural Stem Cells as an Adjuvant to Radiation for the Treatment of Metastatic Lung Cancer. 
  • Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 
  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 
  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. 
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. 
  • Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. 
  • No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. 
  • Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. 
  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-small cell lung cancer clinical practice guidelines in oncology. 
  • Non-small cell lung cancer, version 2.2013. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Non-small cell lung cancer: FDG-PET imaging. 
  • Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. 
  • Noninvasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. 
  • Novel Technologies for Improved Treatment Outcome and Patient Safety in Cancer Radiotherapy. 
  • Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non-Small Cell Lung Cancer Survival. 
  • Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer. 
  • Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival. 
  • Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. 
  • Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review. 
  • Oligoreview of Non-Small Cell Lung Cancer Oligometastases. 
  • Oncologic Equivalence of Minimally Invasive Lobectomy: The Scientific and Practical Arguments. 
  • Optimal weight in estimating and comparing areas under the receiver operating characteristic curve using longitudinal data. 
  • Organizing disparate, seemingly chaotic data into a meaningful and useful order. 
  • Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? 
  • Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. 
  • Outcomes after treatment of 17,378 patients with locally advanced (T3N0-2) non-small-cell lung cancer. 
  • Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. 
  • Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients. 
  • Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer. 
  • Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. 
  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. 
  • Overdiagnosis in low-dose computed tomography screening for lung cancer. 
  • Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma. 
  • Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. 
  • Overview of genetic and molecular events in the pathogenesis of lung cancer. 
  • Overview of stereotactic body radiotherapy and the nursing role. 
  • PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. 
  • Panel of serum biomarkers for the diagnosis of lung cancer. 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. 
  • Pathologic staging of the mediastinum: when and how? 
  • Patient education level as a predictor of survival in lung cancer clinical trials. 
  • Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. 
  • Patient-reported distress as an early warning sign of unmet palliative care needs and increased healthcare utilization in patients with advanced cancer. 
  • Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. 
  • Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall. 
  • Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. 
  • Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. 
  • Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 
  • Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. 
  • Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. 
  • Perioperative Outcomes and 5-year Survival After Open versus Thoracoscopic Sleeve Resection for Lung Cancer. 
  • Perioperative Outcomes and Survival After Preoperative Immunotherapy for Non-Small Cell Lung Cancer. 
  • Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). 
  • Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. 
  • Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. 
  • Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. 
  • Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. 
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. 
  • Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. 
  • Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. 
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. 
  • Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. 
  • Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. 
  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. 
  • Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. 
  • Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 
  • Pilot Study of the Performance of 19-G Needle in Endobronchial Ultrasound-guided Transbronchial Aspiration for the Diagnosis and Testing of Molecular Markers in Lung Cancer. 
  • Placebo-controlled randomized study of hydrazine sulfate in lung cancer. 
  • Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. 
  • Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. 
  • Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. 
  • Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. 
  • Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. 
  • Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. 
  • Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer. 
  • Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial. 
  • Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. 
  • Potentially functional genetic variants of VAV2 and PSMA4 in the immune-activation pathway and non-small cell lung cancer survival. 
  • Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: A case-control analysis. 
  • Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. 
  • Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients. 
  • Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. 
  • Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. 
  • Precision treatment for metastatic non-small cell lung cancer: A conceptual overview. 
  • Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. 
  • Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. 
  • Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. 
  • Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. 
  • Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. 
  • Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. 
  • Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. 
  • Prognostic significance of a complement factor H autoantibody in early stage NSCLC. 
  • Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. 
  • Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. 
  • Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. 
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. 
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. 
  • Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. 
  • Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. 
  • Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. 
  • Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. 
  • Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. 
  • Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. 
  • Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. 
  • Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. 
  • Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. 
  • Pulmonary function testing after stereotactic body radiotherapy to the lung. 
  • Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. 
  • Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. 
  • Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. 
  • Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy. 
  • Quality of life outcomes are equivalent after lobectomy in the elderly. 
  • Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer. 
  • Quantifying the safety benefits of wedge resection: a society of thoracic surgery database propensity-matched analysis. 
  • RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • ROC curve estimation under test-result-dependent sampling. 
  • ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. 
  • Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB). 
  • Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations. 
  • Racial and Ethnic Differences in Lung Cancer Surgical Stage: An STS Database Study. 
  • Racial and ethnic inequities of palliative care use among advanced Non-Small cell lung cancer patients in the US. 
  • Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer. 
  • Radiation therapy for oligometastatic non-small cell lung cancer. 
  • Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone? 
  • Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer. 
  • Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. 
  • Radiofrequency ablation for primary lung cancer and pulmonary metastases. 
  • Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. 
  • Radiomics analysis using stability selection supervised component analysis for right-censored survival data. 
  • Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. 
  • Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. 
  • Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. 
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. 
  • Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Rb and p16INK4a expression in resected non-small cell lung tumors. 
  • Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 
  • Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. 
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. 
  • Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. 
  • Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. 
  • Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. 
  • Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Reply to M.S. Hofman et al. 
  • Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV. 
  • Reply: To PMID 23545195. 
  • Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. 
  • Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. 
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. 
  • Response to Comment on "A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Nonsmall-cell Lung Cancer". 
  • Response. 
  • Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. 
  • Rethinking Autoantibody Signature Panels for Cancer Diagnosis. 
  • Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. 
  • Right-Sided Versus Left-Sided Pneumonectomy After Induction Therapy for Non-Small Cell Lung Cancer. 
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 
  • Risk calculators are useful but.... 
  • Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. 
  • Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells. 
  • Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. 
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. 
  • SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise. 
  • SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. 
  • SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. 
  • SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 
  • Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. 
  • Segmentectomy and Lung Cancer: Why, When, How, and How Good? 
  • Selection bias, phase II trials, and the FDA accelerated approval process. 
  • Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. 
  • Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Severity of emphysema predicts location of lung cancer and 5-y survival of patients with stage I non-small cell lung cancer. 
  • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. 
  • Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. 
  • Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. 
  • Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). 
  • Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"? 
  • Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. 
  • Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. 
  • Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival. 
  • Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. 
  • Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. 
  • Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. 
  • Smoking-related genomic signatures in non-small cell lung cancer. 
  • Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database. 
  • Spatial-temporal variability of radiomic features and its effect on the classification of lung cancer histology. 
  • Squamous non-small cell lung cancer as a distinct clinical entity. 
  • Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 
  • Stage I NSCLC: elucidating the prognostic factors. 
  • Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. 
  • Stage IA non-small cell lung cancer: a small proportion of cases in the general population. 
  • Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. 
  • Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Staging techniques for lung cancer. 
  • Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report. 
  • Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer. 
  • Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. 
  • Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. 
  • Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. 
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. 
  • Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. 
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 
  • Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. 
  • Surgery versus SABR for resectable non-small-cell lung cancer. 
  • Surgery versus stereotactic body radiation therapy for operable stage I non-small cell lung cancer: Can we achieve equipoise? 
  • Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. 
  • Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-Stage Lung Cancer. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. 
  • Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 
  • Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer. 
  • Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. 
  • Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. 
  • Survival after radiation for stage I and II non-small cell lung cancer with positive margins. 
  • Survival in the elderly after pneumonectomy for early-stage non-small cell lung cancer: a comparison with nonoperative management. 
  • Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. 
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. 
  • Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. 
  • TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. 
  • TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. 
  • TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. 
  • Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 
  • Targeted therapy for non-small cell lung cancer. 
  • TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. 
  • Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. 
  • Technology evaluation: BLP-25, Biomira Inc. 
  • Temporal trends in the management of potentially resectable lung cancer. 
  • Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. 
  • The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. 
  • The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. 
  • The Effect of Tumor Size and Histologic Findings on Outcomes After Segmentectomy vs Lobectomy for Clinically Node-Negative Non-Small Cell Lung Cancer. 
  • The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 
  • The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. 
  • The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older With Lung Cancer. 
  • The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. 
  • The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth. 
  • The Quality of Peer-Reviewed Publications on Surgery for Early Stage Lung Cancer Within the Veterans Health Administration. 
  • The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. 
  • The Society of Thoracic Surgeons Composite Score Rating for Pulmonary Resection for Lung Cancer. 
  • The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 
  • The effect of prior pneumonectomy or lobectomy on subsequent lung transplantation. 
  • The evolving role of radiotherapy in treatment of oligometastatic NSCLC. 
  • The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons. 
  • The impact of pre-radiotherapy surgery on radiation-induced lung injury. 
  • The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer. 
  • The importance of chemotherapy dose intensity in lung cancer. 
  • The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer. 
  • The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 
  • The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. 
  • The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. 
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. 
  • The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer. 
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. 
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. 
  • The role of immunotherapy in fusion-driven lung cancer. 
  • The role of stem cells in airway repair: implications for the origins of lung cancer. 
  • The role of thoracoscopic pneumonectomy in the management of non-small cell lung cancer: A multicenter study. 
  • The roles of MASPIN expression and subcellular localization in non-small cell lung cancer. 
  • The surgical management of lung cancer. 
  • The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. 
  • Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. 
  • Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 
  • Thoracoscopic Lobectomy for Non-small Cell Lung Cancer. 
  • Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. 
  • Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. 
  • Thoracoscopic lobectomy for the management of non-small cell lung cancer. 
  • Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. 
  • Thoracoscopic lobectomy: evolving and improving. 
  • Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). 
  • Tirapazamine: a hypoxia-activated topoisomerase II poison. 
  • Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. 
  • Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 
  • Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. 
  • Translating genomics into clinical practice: applications in lung cancer. 
  • Transmission of cancer with cadaveric donor organs. 
  • Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. 
  • Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. 
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. 
  • Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy. 
  • Tumor Size, Histology, and Survival After Stereotactic Ablative Radiotherapy and Sublobar Resection in Node-negative Non-small Cell Lung Cancer. 
  • Tumor acquisition for biomarker research in lung cancer. 
  • Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. 
  • Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. 
  • Ultrasound: the pulmonologist's new best friend. 
  • Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer. 
  • Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. 
  • Update in non-small cell lung cancer. 
  • Update: vinorelbine (navelbine) in non-small cell lung cancer. 
  • Use and Outcomes of Minimally Invasive Lobectomy for Stage I Non-Small Cell Lung Cancer in the National Cancer Data Base. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Using immunotherapy to target EGF in patients with NSCLC. 
  • Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. 
  • VATS and Minimally Invasive Resection in Early-Stage NSCLC. 
  • VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance). 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). 
  • Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. 
  • Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. 
  • Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. 
  • Value of intraoperative pleural lavage in staging non-small cell lung cancer. 
  • Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. 
  • Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. 
  • Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. 
  • Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. 
  • Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. 
  • Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. 
  • Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. 
  • Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. 
  • Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. 
  • Videothoracoscopic mediastinal lymphadenectomy. 
  • Vinorelbine (Navelbine) in non-small cell lung cancer: future directions. 
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. 
  • Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. 
  • What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. 
  • What's next for immunotherapy in locally advanced NSCLC? 
  • When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. 
  • X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma cells. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • [A study of E-cadherin and beta-catenin expression and their correlation with prognosis of nonsmall cell lung carcinoma]. 
  • [The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer]. 
  • c-Maf: a bad influence in the education of macrophages. 
  • xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society